Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream

Arcutis Biotherapeutics (ARQT) announced new data from the Integument-Infant Phase 2 trial demonstrating that Zoryve cream 0.05% reduced signs and symptoms of atopic dermatitis, the most common form of eczema, in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. These results build upon the topline results announced last month and further support the potential of investigational Zoryve cream as a treatment option for this youngest and very vulnerable population. The results were presented today during a late-breaking podium presentation at the 2026 American Academy of Dermatology, AAD, Annual Meeting in Denver, CO.